生物制剂与JAK抑制剂治疗特应性皮炎感染风险:BioDay研究
这项前瞻性多中心队列研究纳入1793例中重度特应性皮炎患者,比较生物制剂与JAK抑制剂在真实世界中的感染风险。JAK抑制剂感染率明显高于生物制剂,疱疹感染尤为突出,JAK抑制剂较度普利尤单抗的感染风险显著增加,既往皮肤感染史为独立危险因素。
要点
- JAK抑制剂感染率(58.4–65.5/100患者年)高于生物制剂(13.6–22.0)。
- JAK抑制剂较度普利尤单抗感染风险显著增加,HR约4.0–4.2。
- 既往病毒或真菌皮肤感染史为独立感染危险因素。
核心结论
- 中重度特应性皮炎患者中,JAK抑制剂治疗较度普利尤单抗增加感染风险,尤其疱疹感染。
研究设计与样本
- 前瞻性多中心队列研究,纳入BioDay注册系统中2017年10月至2024年7月年龄≥12岁使用生物制剂或JAK抑制剂的患者,共1793例,4044.1患者年,1886个生物制剂治疗周期和480个JAK抑制剂治疗周期。
主要发现
- 共794例感染,JAK抑制剂感染率为58.4–65.5/100患者年,生物制剂为13.6–22.0/100患者年。
- 疱疹感染共195例(24.6%),JAK抑制剂为13.6–19.8/100患者年,生物制剂为3.0–3.6/100患者年。
- 与度普利尤单抗相比,阿布昔替尼HR 4.1(95%CI 3.1–5.5)、巴瑞替尼HR 4.2(95%CI 2.9–6.2)、乌帕替尼HR 4.0(95%CI 3.2–5.0),均p<0.0001;曲罗芦单抗HR 1.4(95%CI 1.0–2.0,p=0.039)。
- JAK抑制剂较度普利尤单抗严重感染率更高,但绝对数低且关联未持续显著。
- 既往感染史(主要为病毒或真菌皮肤感染)为独立危险因素:病毒性HR 1.9(95%CI 1.4–2.6,p<0.0001),真菌性HR 2.4(95%CI 1.3–4.4,p=0.003)。
关键数值与推荐
- JAK抑制剂感染率58.4–65.5/100患者年,生物制剂13.6–22.0/100患者年。
- 疱疹感染JAK抑制剂13.6–19.8/100患者年,生物制剂3.0–3.6/100患者年。
- 阿布昔替尼HR 4.1(95%CI 3.1–5.5)、巴瑞替尼HR 4.2(95%CI 2.9–6.2)、乌帕替尼HR 4.0(95%CI 3.2–5.0),均p<0.0001。
- 曲罗芦单抗HR 1.4(95%CI 1.0–2.0,p=0.039)。
- 既往病毒性皮肤感染HR 1.9(95%CI 1.4–2.6,p<0.0001),真菌性HR 2.4(95%CI 1.3–4.4,p=0.003)。
临床怎么用
- 选择靶向治疗时应评估患者既往皮肤感染史,尤其病毒或真菌感染,以个体化权衡JAK抑制剂的感染风险。
- 对使用JAK抑制剂的中重度特应性皮炎患者,需加强疱疹等感染的监测与预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice. OBJECTIVES: To assess the differential infection risk of biologic and JAKi treatment in patients with moderate-to-severe AD in a real-world setting. METHODS: This prospective, multicentre study evaluated treatment-emergent infections in patients (age ≥ 12 years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient-years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio-/JAKi-naïve patients. RESULTS: In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4-65.5/100 PY) compared to biologics (13.6-22.0), especially for herpes infections (n = 195, 24.6%; JAKi 13.6-19.8 vs. biologicals 3.0-3.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1-5.5; baricitinib HR 4.2, 95% CI: 2.9-6.2; upadacitinib HR 4.0, 95% CI: 3.2-5.0; all p < 0.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0-2.0, p = 0.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4-2.6, p < 0.0001; 2.4, 1.3-4.4, p = 0.003, resp.), was identified as an independent factor associated with infection. CONCLUSIONS: This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate-to-severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient-specific risks such as prior skin infections.
引用
- van der Gang LF, Atash K, Zuithoff NPA, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol. 2025. PMID: 40176741. doi:10.1111/jdv.20674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。